SG10201805064SA - Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains - Google Patents

Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

Info

Publication number
SG10201805064SA
SG10201805064SA SG10201805064SA SG10201805064SA SG10201805064SA SG 10201805064S A SG10201805064S A SG 10201805064SA SG 10201805064S A SG10201805064S A SG 10201805064SA SG 10201805064S A SG10201805064S A SG 10201805064SA SG 10201805064S A SG10201805064S A SG 10201805064SA
Authority
SG
Singapore
Prior art keywords
signal
isv
protein interference
give rise
tendency
Prior art date
Application number
SG10201805064SA
Inventor
Judith Baumeister
Marie-Paule Bouche
Carlo Boutton
Marie-Ange Buyse
Veerle Snoeck
Stephanie Staelens
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47423024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201805064S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2011/067132 external-priority patent/WO2012042026A1/en
Priority claimed from PCT/EP2012/061304 external-priority patent/WO2012175400A1/en
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of SG10201805064SA publication Critical patent/SG10201805064SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; - modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal. Figure 1A 86 93
SG10201805064SA 2011-06-23 2012-06-25 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains SG10201805064SA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161500464P 2011-06-23 2011-06-23
US201161500360P 2011-06-23 2011-06-23
US201161541368P 2011-09-30 2011-09-30
PCT/EP2011/067132 WO2012042026A1 (en) 2010-09-30 2011-09-30 Biological materials related to c-met
US13/435,567 US8703135B2 (en) 2010-09-30 2012-03-30 Biological materials related to c-Met
PCT/EP2012/061304 WO2012175400A1 (en) 2011-06-23 2012-06-14 Serum albumin binding proteins

Publications (1)

Publication Number Publication Date
SG10201805064SA true SG10201805064SA (en) 2018-07-30

Family

ID=47423024

Family Applications (4)

Application Number Title Priority Date Filing Date
SG10201605048XA SG10201605048XA (en) 2011-06-23 2012-06-25 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SG2013084678A SG194982A1 (en) 2011-06-23 2012-06-25 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SG10201707604SA SG10201707604SA (en) 2011-06-23 2012-06-25 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SG10201805064SA SG10201805064SA (en) 2011-06-23 2012-06-25 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

Family Applications Before (3)

Application Number Title Priority Date Filing Date
SG10201605048XA SG10201605048XA (en) 2011-06-23 2012-06-25 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SG2013084678A SG194982A1 (en) 2011-06-23 2012-06-25 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SG10201707604SA SG10201707604SA (en) 2011-06-23 2012-06-25 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

Country Status (22)

Country Link
US (11) US20180009888A9 (en)
EP (1) EP2723769B2 (en)
JP (6) JP6258199B2 (en)
KR (7) KR102025035B1 (en)
CN (5) CN108659120A (en)
AU (7) AU2012273929B2 (en)
BR (3) BR112013032145B1 (en)
CA (3) CA2837998C (en)
DK (1) DK2723769T4 (en)
ES (1) ES2622006T5 (en)
HU (1) HUE031828T2 (en)
IL (4) IL250396B (en)
IN (1) IN2014CN00373A (en)
LT (1) LT2723769T (en)
MX (2) MX350074B (en)
PH (1) PH12017501178A1 (en)
PL (1) PL2723769T5 (en)
PT (1) PT2723769T (en)
RU (2) RU2019128430A (en)
SG (4) SG10201605048XA (en)
WO (1) WO2012175741A2 (en)
ZA (1) ZA201309295B (en)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2860453T3 (en) 2009-10-30 2021-10-05 Novartis Ag Universal libraries of type III fibronectin underside binding domain
EP4234698A3 (en) 2010-05-06 2023-11-08 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
WO2012175400A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Serum albumin binding proteins
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
EP2944654A1 (en) 2011-06-23 2015-11-18 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
US20180009888A9 (en) 2011-06-23 2018-01-11 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
TW201321405A (en) 2011-08-17 2013-06-01 Glaxo Group Ltd Modified proteins and peptides
WO2013073968A2 (en) * 2011-09-12 2013-05-23 Industrial Research Limited Agents for modulation of cell signalling
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
EP3252075A1 (en) 2011-11-04 2017-12-06 Novartis AG Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
CN104781277A (en) * 2012-09-13 2015-07-15 诺华股份有限公司 antigen binding molecule with terminal modification
EP3092049A1 (en) 2014-01-08 2016-11-16 Flodesign Sonics Inc. Acoustophoresis device with dual acoustophoretic chamber
CA2948945C (en) * 2014-05-16 2023-08-08 Ablynx Nv Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
BR122018009619B1 (en) 2014-05-16 2024-01-02 Ablynx N.V IMPROVED IMMUNOGLOBULIN VARIABLE DOMAINS
RU2746738C2 (en) 2014-05-16 2021-04-20 Аблинкс Нв Improved variable domains of immunoglobulins
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
WO2016118733A1 (en) 2015-01-21 2016-07-28 Inhibrx Biopharma LLC Non-immunogenic single domain antibodies
AU2016239948B2 (en) 2015-03-31 2022-03-17 Sorriso Pharmaceuticals, Inc. Polypeptides
AU2016239844B2 (en) 2015-04-02 2021-05-13 Ablynx N.V. Bispecific CXCR4-CD-4 polypeptides with potent anti-HIV activity
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11420136B2 (en) 2016-10-19 2022-08-23 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
RS59376B1 (en) 2015-05-13 2019-11-29 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
EP3294319B1 (en) 2015-05-13 2024-04-24 Ablynx NV T cell recruiting polypeptides based on cd3 reactivity
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
EP3368569B1 (en) 2015-10-30 2021-02-24 Ablynx NV Polypeptides against il-23
TWI746473B (en) * 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 Single domain antibodies directed against intracellular antigens
CA3005082A1 (en) * 2015-11-12 2017-05-18 Ablynx Nv Improved p2x7 receptor binders and polypeptides comprising the same
NO2768984T3 (en) 2015-11-12 2018-06-09
WO2017080850A1 (en) * 2015-11-13 2017-05-18 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains
WO2017085172A2 (en) 2015-11-18 2017-05-26 Ablynx Nv Improved serum albumin binders
TWI754622B (en) 2015-11-18 2022-02-11 美商默沙東藥廠 Ctla4 binders
AU2016355568A1 (en) 2015-11-18 2018-06-21 Merck Sharp & Dohme Llc PD1/CTLA4 Binders
KR102317574B1 (en) 2015-11-18 2021-10-26 머크 샤프 앤드 돔 코포레이션 Pd1 and/or lag3 binders
RU2018122255A (en) 2015-11-27 2019-12-19 Аблинкс Нв CD40L INHIBITING POLYPEPTIDES
SI3383425T1 (en) 2015-12-04 2020-11-30 Boehringer Ingelheim International Gmbh Biparatopic polypeptides antagonizing wnt signaling in tumor cells
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
JP7150618B2 (en) 2016-06-23 2022-10-11 アブリンクス エン．ヴェー． Improved Pharmacokinetic Assays for Immunoglobulin Single Variable Domains
EP3512880A1 (en) 2016-09-15 2019-07-24 Ablynx NV Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
CA3043515A1 (en) 2016-11-16 2018-05-24 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
IL310340A (en) 2016-12-07 2024-03-01 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
AU2018209151A1 (en) 2017-01-17 2019-07-25 Ablynx Nv Improved serum albumin binders
US11897944B2 (en) 2017-01-17 2024-02-13 Ablynx N.V. Immunoglobulin single variable domain (ISVD) capable of binding to serum albumin
MX2019011702A (en) 2017-03-31 2019-11-01 Ablynx Nv Improved immunogenicity assays.
MY200744A (en) 2017-05-31 2024-01-13 Boehringer Ingelheim Int Gmbh Polypeptides antagonizing wnt signaling in tumor cells
CA3064469A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Mmp13 binding immunoglobulins
MX2019014397A (en) 2017-06-02 2020-02-10 Merck Patent Gmbh Polypeptides binding adamts5, mmp13 and aggrecan.
EP3630818A1 (en) 2017-06-02 2020-04-08 Ablynx NV Aggrecan binding immunoglobulins
MX2019014400A (en) * 2017-06-02 2020-02-10 Merck Patent Gmbh Adamts binding immunoglobulins.
KR102625929B1 (en) 2017-07-19 2024-01-16 브이아이비 브이지더블유 Serum albumin binder
WO2019038986A1 (en) 2017-08-23 2019-02-28 本田技研工業株式会社 Air bag device for saddle-type vehicles
US11873347B2 (en) 2017-10-31 2024-01-16 Vib Vzw Antigen-binding chimeric proteins and methods and uses thereof
BR112020009889A2 (en) 2017-12-14 2020-11-03 Flodesign Sonics, Inc. acoustic transducer driver and controller
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TW202016151A (en) 2018-06-09 2020-05-01 德商百靈佳殷格翰國際股份有限公司 Multi-specific binding proteins for cancer treatment
MA53130A (en) * 2018-07-10 2021-05-19 Regeneron Pharma TARGET DRUG INTERFERENCE MITIGATION METHODS IN AN IMMUNOLOGICAL ASSAY OF ANTI-DRUG ANTIBODIES (ADA)
FR3088640A1 (en) 2018-10-14 2020-05-22 Smart Diagnostix Pharma NOVEL POLYPEPTIDE SPECIFICALLY BINDING TO PROTEIN P16
EP3962599A1 (en) 2019-04-30 2022-03-09 Vib Vzw Cystic fibrosis transmembrane conductance regulator stabilizing agents
EP3986931A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
EP3986571A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
TW202128756A (en) 2019-10-02 2021-08-01 德商百靈佳殷格翰國際股份有限公司 Multi-specific binding proteins for cancer treatment
GB201914468D0 (en) 2019-10-07 2019-11-20 Crescendo Biologics Ltd Binding Molecules
WO2021105438A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
AU2020397210A1 (en) 2019-12-06 2022-07-28 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting TNFa and OX40L
CN114981300A (en) 2019-12-06 2022-08-30 艾伯霖克斯公司 Polypeptides comprising immunoglobulin single variable domains targeting TNF alpha and IL-23
BR112022010223A2 (en) 2019-12-09 2022-09-06 Ablynx Nv POLYPEPTIDES COMPRISING SINGLE IMMUNOGLOBULIN VARIABLE DOMAINS THAT TARGET INTERLEUKIN 13 (IL-13) AND THYMIC STROMAL LYMPHOPOIETIN (TSLP)
AR120698A1 (en) 2019-12-09 2022-03-09 Ablynx Nv POLYPEPTIDES COMPRISING SINGLE VARIABLE DOMAINS OF IMMUNOGLOBULIN TARGETING IL-13 AND TSLP
JP2023506961A (en) 2019-12-20 2023-02-20 フエー・イー・ベー・フエー・ゼツト・ウエー Nanobody exchange chromatography
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
IL295892A (en) 2020-02-25 2022-10-01 Vib Vzw Leucine-rich repeat kinase 2 allosteric modulators
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
EP4217390A1 (en) 2020-09-25 2023-08-02 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
MX2023006604A (en) 2020-12-04 2023-06-19 Tidal Therapeutics Inc Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof.
BR112023011782A2 (en) 2020-12-14 2023-10-31 Takeda Pharmaceuticals Co CONDITIONALLY BIESPECIFIC BINDING PROTEINS
TW202241947A (en) 2020-12-18 2022-11-01 比利時商艾伯霖克斯公司 Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
EP4263602A1 (en) 2020-12-18 2023-10-25 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha
MX2023007299A (en) 2020-12-18 2023-07-04 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity.
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
CN117794566A (en) 2021-02-05 2024-03-29 Vib研究所 Sha Bei viral binding agents
EP4288095A1 (en) 2021-02-05 2023-12-13 Vib Vzw Sarbecovirus binders
CA3211270A1 (en) 2021-02-19 2022-08-25 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
CN113173978B (en) * 2021-04-22 2024-03-01 温州医科大学 Polypeptide with binding affinity to HPV16E6 protein and application thereof
WO2023016828A2 (en) 2021-07-30 2023-02-16 Vib Vzw Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
TW202330596A (en) * 2021-11-29 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Modified protein or peptide
WO2023110190A1 (en) 2021-12-13 2023-06-22 Heraeus Medical Gmbh Tests and methods for detecting bacterial infection
WO2023111266A1 (en) 2021-12-17 2023-06-22 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123
WO2023135198A1 (en) 2022-01-12 2023-07-20 Vib Vzw Human ntcp binders for therapeutic use and liver-specific targeted delivery
WO2023164551A1 (en) 2022-02-23 2023-08-31 Takeda Pharmaceutical Company Limited Conditionally bispecific binding proteins
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023222825A1 (en) 2022-05-18 2023-11-23 Vib Vzw Sarbecovirus spike s2 subunit binders
WO2023240156A1 (en) 2022-06-08 2023-12-14 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
US20240109965A1 (en) 2022-06-14 2024-04-04 Ablynx N.V. Immunoglobulin single variable domains targeting t cell receptor
WO2024023271A1 (en) 2022-07-27 2024-02-01 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor
WO2024068744A1 (en) 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
EP4357778A1 (en) 2022-10-20 2024-04-24 Heraeus Medical GmbH Treatment of microbial infections diagnosed using the biomarker d-lactate

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545106C3 (en) 1963-07-16 1979-05-31 Union Carbide Corp., New York, N.Y. (V.St.A.) Process for the production of linear polyarylene polyethers
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9016299D0 (en) * 1990-07-25 1990-09-12 Brien Caroline J O Binding substances
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
ZA919299B (en) 1990-11-26 1992-08-26 Akzo Nv Method for the production of antibodies
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
ATE497171T1 (en) 1999-07-05 2011-02-15 Leuven K U Res & Dev VON WILLEBRAND FACTOR ACTIVITY PROOF
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
WO2002026829A1 (en) 2000-09-25 2002-04-04 Rega Stichting Vzw Method for the production of human antibodies, antibodies thus obtained and their use in therapy and diagnosis
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
FR2846667B1 (en) 2002-11-06 2004-12-31 Pasteur Institut VARIABLE FRAGMENTS OF SINGLE-CHAIN CAMELIDE ANTIBODIES DIRECTED AGAINST BETA-AMYLOID PEPTIDE 1-42 AND THEIR APPLICATIONS FOR DIAGNOSIS AND TREATMENT OF NEUROAGREGATIVE DISEASES
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
EP1570267B1 (en) 2002-12-03 2011-10-12 UCB Pharma, S.A. Assay for identifying antibody producing cells
JP2006523090A (en) * 2002-12-27 2006-10-12 ドマンティス リミテッド Bispecific single domain antibody specific for ligand and for ligand receptor
CN101412759A (en) 2003-01-10 2009-04-22 埃博灵克斯股份有限公司 Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
WO2004065416A2 (en) * 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20070087331A1 (en) 2003-05-15 2007-04-19 Cytos Biotechnology Ag Selection of b cells with specificity if interest: method of preparation and use
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
KR20070117002A (en) 2003-11-04 2007-12-11 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 Hyperlipemia/hyperalbuminemia model animal
AU2005267720B2 (en) 2004-08-05 2012-02-23 Genentech, Inc. Humanized anti-cmet antagonists
CA2588892A1 (en) 2004-12-02 2006-06-08 Dormantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EP1888640B1 (en) † 2005-05-18 2012-03-14 Ablynx N.V. Improved nanobodies against tumor necrosis factor-alpha
PL3415535T3 (en) * 2005-05-20 2021-06-14 Ablynx N.V. Improved nanobodies tm for the treatment of aggregation-mediated disorders
DE102005023617A1 (en) * 2005-05-21 2006-11-23 Aspre Ag Method for mixing colors in a display
US7989219B2 (en) * 2005-05-31 2011-08-02 Canon Kabushiki Kaisha Bispecific capturing molecule
JP2007008925A (en) * 2005-05-31 2007-01-18 Canon Inc Target substance-catching molecule
US7875465B2 (en) 2005-05-31 2011-01-25 Canon Kabushiki Kaisha Target substance capturing molecule
EP1957536A2 (en) 2005-12-01 2008-08-20 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
EP1957537A2 (en) 2005-12-01 2008-08-20 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
FR2894741B1 (en) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales SATELLITE RECEPTION CHAIN
EP1976991A1 (en) 2006-01-24 2008-10-08 Domantis Limited Fusion proteins that contain natural junctions
EP2004693B1 (en) 2006-03-30 2012-06-06 Novartis AG Compositions and methods of use for antibodies of c-met
US7741273B2 (en) * 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
MX2009001293A (en) * 2006-08-03 2009-02-11 Astrazeneca Ab Antibodies directed to â¿vãy6 and uses thereof.
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
JP2010502208A (en) * 2006-09-08 2010-01-28 アブリンクス エン．ヴェー． Serum albumin binding protein with long half-life
ATE536369T1 (en) * 2006-10-11 2011-12-15 Ablynx Nv ESSENTIALLY PH-INDEPENDENT AMINO ACID SEQUENCES BINDING TO SERUM PROTEINS, COMPOUNDS CONTAINING SAME, AND THEIR USE
JP2010511397A (en) 2006-12-05 2010-04-15 アブリンクス エン．ヴェー． Peptides that can bind to serum proteins
CA2672049C (en) 2006-12-08 2016-05-10 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
WO2008071447A2 (en) * 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
EP2097451A2 (en) * 2006-12-22 2009-09-09 Ablynx N.V. Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
EP2121757A2 (en) 2007-02-21 2009-11-25 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
MX2009012650A (en) * 2007-05-24 2010-02-18 Ablynx Nv Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders.
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
AR062123A1 (en) * 2007-07-27 2008-10-15 Inst Nac De Tecnologia Agropec VHH MONOMERIC DOMAIN DERIVED FROM ANTI-VP6 CAMELID ANTIBODIES, DIMERIC DOMAIN, ROTAVIRUS IMMUNODETECTION METHOD, COMPOSITIONS, ROTAVIRUS INFECTION PREVENTION AND TREATMENT METHODS
EP2197491A4 (en) * 2007-09-04 2011-01-12 Univ California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
EP2201040A1 (en) * 2007-09-24 2010-06-30 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses thereof
WO2009068630A1 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Immunoglobulin constructs
US8030454B2 (en) * 2007-12-28 2011-10-04 Genentech, Inc. Anti-hedgehog antibodies
EP2250201B1 (en) * 2008-01-29 2014-04-30 Ludwig Institute for Cancer Research Ltd. Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
AU2009237662A1 (en) * 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
DE102008023620A1 (en) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Function unit with an invocable function and method for calling it
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
US7858729B2 (en) 2008-05-29 2010-12-28 Novomer, Inc. Methods of controlling molecular weight distribution of polymers and compositions thereof
DK2285408T3 (en) 2008-06-05 2019-02-04 Ablynx Nv AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
US20110200525A1 (en) * 2008-10-09 2011-08-18 Patz Jr Edward F Vhh antibody fragments for use in the detection and treatment of cancer
US8372808B2 (en) 2008-10-31 2013-02-12 Wisconsin Alumni Research Foundation Suppression of glial fibrillary acidic protein
WO2010100135A1 (en) † 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
CN104127880A (en) 2009-03-27 2014-11-05 葛兰素集团有限公司 Drug fusion and conjugate
US8748581B2 (en) * 2009-04-10 2014-06-10 Ablynx N.V. Anti-IL-6R polypeptides and pharmaceutical compositions thereof
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
WO2011003622A1 (en) * 2009-07-10 2011-01-13 Ablynx N.V. Method for the production of variable domains
US8306355B2 (en) 2009-07-13 2012-11-06 Sharp Laboratories Of America, Inc. Methods and systems for reducing compression artifacts
EP2507262A1 (en) * 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP2513145B1 (en) * 2009-12-14 2018-01-24 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
AR079645A1 (en) * 2009-12-18 2012-02-08 Sanofi Aventis ANTAGONIST ANTIBODIES AND THEIR FABRATIONS FAB AGAINST THE PROTEIN OF HUMAN PLATQUETTE MEMBRANES GLICOPROTEIN VI (GPVI) AND ITS USES
KR101721187B1 (en) 2009-12-23 2017-03-29 에스바테크 - 어 노바티스 컴파니 엘엘씨 Method for decreasing immunogenicity
PE20130527A1 (en) * 2010-03-03 2013-05-09 Boehringer Ingelheim Int BIPARATOPIC A-BETA BINDING POLYPEPTIDES
AU2011226103C1 (en) 2010-03-10 2016-04-28 Genmab A/S Monoclonal antibodies against c-Met
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
US20130109842A1 (en) 2010-04-30 2013-05-02 Ablynx N.V. Amino acid sequences of nanobodies directed against p19 subunit of the heterodimeric cytokine il-23
EP3546483A1 (en) * 2010-05-20 2019-10-02 Ablynx N.V. Biological materials related to her3
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
WO2012175400A1 (en) * 2011-06-23 2012-12-27 Ablynx Nv Serum albumin binding proteins
MA34820B1 (en) * 2011-01-06 2014-01-02 Glaxo Group Ltd LIGANDISE BINDING TO TGF-BETA RECEPTOR II
JP6130350B2 (en) 2011-03-30 2017-05-17 アブリンクス エン．ヴェー． Methods of treating immune disorders with single domain antibodies against TNFα
WO2012130314A1 (en) † 2011-03-31 2012-10-04 Elara Pharmaceuticals Gmbh Composition comprising docetaxel
US20180009888A9 (en) 2011-06-23 2018-01-11 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US20150344568A1 (en) 2011-06-23 2015-12-03 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US9499612B2 (en) 2011-07-27 2016-11-22 Glaxo Group Limited Antigen binding constructs
TW201321405A (en) 2011-08-17 2013-06-01 Glaxo Group Ltd Modified proteins and peptides
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
US8614548B2 (en) 2012-01-19 2013-12-24 Sonoco Development Incorporated Electroluminescent display and method for production
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US20130316143A1 (en) 2012-05-22 2013-11-28 Owens Corning Intellectual Capital, Llc Laminated foam product and methods for making laminated foam products
WO2014111550A1 (en) † 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
RU2746738C2 (en) * 2014-05-16 2021-04-20 Аблинкс Нв Improved variable domains of immunoglobulins
AU2015334984A1 (en) 2014-10-21 2017-04-13 Ablynx Nv Treatment of IL-6R related diseases
NO2768984T3 (en) * 2015-11-12 2018-06-09
AU2016355568A1 (en) 2015-11-18 2018-06-21 Merck Sharp & Dohme Llc PD1/CTLA4 Binders
TWI754622B (en) 2015-11-18 2022-02-11 美商默沙東藥廠 Ctla4 binders
KR102317574B1 (en) 2015-11-18 2021-10-26 머크 샤프 앤드 돔 코포레이션 Pd1 and/or lag3 binders
WO2017085172A2 (en) * 2015-11-18 2017-05-26 Ablynx Nv Improved serum albumin binders
US10626186B2 (en) 2016-01-26 2020-04-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-VWF D'D3 single-domain antibodies and methods of use
IL310340A (en) * 2016-12-07 2024-03-01 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
AU2018209151A1 (en) * 2017-01-17 2019-07-25 Ablynx Nv Improved serum albumin binders
MX2019014400A (en) * 2017-06-02 2020-02-10 Merck Patent Gmbh Adamts binding immunoglobulins.
AR120698A1 (en) * 2019-12-09 2022-03-09 Ablynx Nv POLYPEPTIDES COMPRISING SINGLE VARIABLE DOMAINS OF IMMUNOGLOBULIN TARGETING IL-13 AND TSLP

Also Published As

Publication number Publication date
EP2723769A2 (en) 2014-04-30
PL2723769T5 (en) 2022-10-17
US20210388061A1 (en) 2021-12-16
KR102430693B1 (en) 2022-08-08
US10858418B2 (en) 2020-12-08
BR112013032145A8 (en) 2018-07-03
ES2622006T3 (en) 2017-07-05
US20210403536A1 (en) 2021-12-30
US20180009888A9 (en) 2018-01-11
KR102246924B1 (en) 2021-04-30
JP2018162305A (en) 2018-10-18
SG194982A1 (en) 2013-12-30
US20140199295A1 (en) 2014-07-17
IL250396A0 (en) 2017-03-30
LT2723769T (en) 2017-04-10
BR112013032145A2 (en) 2017-12-05
JP2024050769A (en) 2024-04-10
JP6982400B2 (en) 2021-12-17
BR112013032145B1 (en) 2022-09-20
US20210388062A1 (en) 2021-12-16
AU2021201506A1 (en) 2021-03-25
AU2017204339B2 (en) 2019-03-28
AU2021201506B2 (en) 2023-10-19
BR122018012485B1 (en) 2022-09-20
CA2837998A1 (en) 2012-12-27
WO2012175741A3 (en) 2013-02-14
CN108653728B (en) 2022-11-18
US20170275361A1 (en) 2017-09-28
EP2723769B1 (en) 2017-01-11
KR20240033183A (en) 2024-03-12
CN108653728A (en) 2018-10-16
IL293155A (en) 2022-07-01
KR20210047369A (en) 2021-04-29
JP6869923B2 (en) 2021-05-12
US20170275360A1 (en) 2017-09-28
MX2013014614A (en) 2014-08-01
US20220119497A1 (en) 2022-04-21
KR20140040779A (en) 2014-04-03
KR20190107200A (en) 2019-09-18
US20220298227A9 (en) 2022-09-22
RU2019128430A (en) 2019-10-25
KR102025035B1 (en) 2019-11-04
KR101965462B1 (en) 2019-04-04
JP2021107426A (en) 2021-07-29
CN104203975A (en) 2014-12-10
JP2022031790A (en) 2022-02-22
SG10201707604SA (en) 2017-11-29
PL2723769T3 (en) 2017-07-31
BR122017005075B1 (en) 2022-09-20
AU2024200309A1 (en) 2024-02-08
KR20220114104A (en) 2022-08-17
CA3142288A1 (en) 2012-12-27
US20200325221A1 (en) 2020-10-15
AU2019201606B2 (en) 2021-04-01
AU2017204339A1 (en) 2017-07-13
CN108663504A (en) 2018-10-16
IL293163A (en) 2022-07-01
CA2837998C (en) 2022-03-01
CN104203975B (en) 2018-05-11
JP2014520134A (en) 2014-08-21
AU2020230299A1 (en) 2020-10-01
US11192937B2 (en) 2021-12-07
RU2014102007A (en) 2015-11-27
AU2020230299B2 (en) 2022-10-06
CN108659121A (en) 2018-10-16
ZA201309295B (en) 2015-01-28
ES2622006T5 (en) 2022-10-13
CN108663504B (en) 2021-06-22
CA3141978A1 (en) 2012-12-27
KR20190041513A (en) 2019-04-22
JP2017160230A (en) 2017-09-14
PH12017501178A1 (en) 2018-07-23
AU2018202782B2 (en) 2020-07-16
IL250396B (en) 2022-06-01
KR20180086280A (en) 2018-07-30
SG10201605048XA (en) 2016-07-28
JP6258199B2 (en) 2018-01-10
NZ716279A (en) 2017-07-28
KR102240318B1 (en) 2021-04-15
AU2019201606A1 (en) 2019-04-04
AU2018202782A1 (en) 2018-05-10
DK2723769T3 (en) 2017-04-03
US20200216532A1 (en) 2020-07-09
AU2012273929B2 (en) 2017-04-27
BR122017005075A2 (en) 2019-09-03
HUE031828T2 (en) 2017-08-28
MX350074B (en) 2017-08-25
PT2723769T (en) 2017-04-04
IL229503B (en) 2022-06-01
IN2014CN00373A (en) 2015-04-03
US20230242620A1 (en) 2023-08-03
US20180355031A1 (en) 2018-12-13
CN108659120A (en) 2018-10-16
WO2012175741A2 (en) 2012-12-27
US11192938B2 (en) 2021-12-07
DK2723769T4 (en) 2022-09-05
MX2018007826A (en) 2021-12-08
RU2700630C2 (en) 2019-09-18
IL229503A0 (en) 2014-01-30
NZ617995A (en) 2016-06-24
EP2723769B2 (en) 2022-06-15

Similar Documents

Publication Publication Date Title
PH12017501178A1 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
NZ609363A (en) Methods for determining anti-drug antibody isotypes
NZ602056A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BR112016004437A2 (en) immunotest and cell line selection methods, antibodies and kit
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
JO3812B1 (en) Antibodies that bind to human programmed death ligand 1 (pd-l1)
NZ603492A (en) Humanized anti-factor d antibodies and uses thereof
NZ609824A (en) Immunochromatography devices, methods and kits
MX2014001377A (en) Method for detecting pancreatic cancer.
MX2013001042A (en) Pancreatic cancer biomarkers and uses thereof.
NZ600828A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BR112012030788B8 (en) MONOCLONAL ANTIBODY, HYBRIDOMA CELL LINE, AND METHODS FOR IDENTIFYING THE PRESENCE AND FOR QUANTITATIVE DETERMINATION OF AN AAD-12 ENZYME
NZ706187A (en) Assays for the detection of anti-tnf drugs and autoantibodies
WO2009137832A3 (en) Autoantibodies in the detection and treatment of cancer
BR112012008665A2 (en) cancer treatment
BR112013027867A2 (en) "method of detecting the level of a sample anti-ip10 antibody, isolated monoclonal antibody or antigen binding portion thereof, hybridoma cell line and kit"
NZ621733A (en) Lung cancer biomarkers and uses thereof
ATE504002T1 (en) DETECTION AND PREDICTION OF PREMATURE BIRTH
PL2185937T3 (en) Method for assaying sepsis in humans
SG10201906124XA (en) Foetal nucleated red blood cell detection
WO2009023331A3 (en) Antibodies and improved test sample handling methods for use in assays for myeloperoxidase
WO2013106778A3 (en) Non-equilibrium two-site assays for linear, ultrasensitive analyte detection
EP2565647A4 (en) Reagent for assaying anti-treponema pallidum antibody
GB201119585D0 (en) Assay
WO2013165969A3 (en) Methods and kits for diagnosing heparin-induced thrombocytopenia